Beyond the Target List: Why Volume-Based Physician Targeting Is Leaving Revenue on the Table

And what MedTech commercial teams can do about it.

(This content originally appeared on the Alpha Sophia blog).

Every MedTech sales leader knows the drill. A new targeting platform gets rolled out. Reps are handed a ranked list of physicians sorted by procedure volume. The top 100 names look promising. The problem? So does every other company’s list — because they’re pulling from the same claims data.

The physician sales targeting category has matured rapidly over the past few years. Platforms like AcuityMD, Medscout, and others have done something genuinely useful: they’ve moved the industry beyond spreadsheets and gut instinct. But as adoption has accelerated, a structural limitation has come into focus. When every commercial team is targeting the same high-volume physicians with the same algorithmic scores, the tool stops being a differentiator and starts being table stakes.

At SmartTRAK and Alpha Sophia, we’ve spent considerable time with MedTech commercial teams navigating exactly this problem. What we’ve seen — and what we’ll be exploring in depth at SmartTRAK’s In2Data conference this November — is that the companies pulling ahead aren’t just targeting better. They’re thinking about commercial intelligence in a fundamentally different way.

“Targeting tells you who to call. Intelligence tells you what to say, why it matters, and whether the market is ready to hear it.”

The Pitfalls Nobody Talks About at the Vendor Demo

Claims data is powerful. But it has a set of structural limitations that are rarely surfaced by the platforms selling it. Here’s what commercial teams are actually running into:

The high-volume physician trap. Ranking physicians by procedure volume creates a self-defeating dynamic: every competitor has the same list. The top 5–10% of proceduralists are the most entrenched, the most solicited, and the hardest to move. Meanwhile, mid-volume and emerging physicians — many of whom are more open to switching, building their practice, and becoming true partners — get ignored.

Data that doesn’t cover the whole market. Most claims-based platforms have significant coverage gaps. Medicare data misses commercially insured patients under 65. Pediatric, Medicaid, and cash-pay populations often don’t appear at all. In categories like wound care and regenerative medicine — where patient mix is highly variable and off-label use is common — CPT-code targeting can be deeply misleading.

Lagged data in a fast-moving environment. Claims data carries inherent processing delays of 60–180 days. In an environment where physicians are moving practices, joining IDNs, shifting their ASC utilization, and responding to evolving reimbursement rules, a rep acting on three-month-old data isn’t acting on reality.

Procedure volume without clinical or market context. Knowing a surgeon performs 200 procedures a year doesn’t tell you whether they’re satisfied with their current device, whether their hospital just signed an exclusive contract with a competitor, what’s driving reimbursement decisions at their institution, or whether a competing technology is gaining share in that specialty. Volume is a quantity metric. Winning requires quality insight.

The commoditization of the rep conversation. When reps walk in armed with the same data as every other company’s rep, physicians notice. Being told your own procedure volume by a third party — again — erodes credibility rather than building it. The consultative value proposition breaks down when the data is no longer differentiated.

A Note from Alpha Sophia: What the Data Is Actually Telling You

At Alpha Sophia, we work at the intersection of commercial intelligence and strategic decision-making for MedTech companies. What we consistently observe is that procedure volume data answers one narrow question: who is already doing this? But it leaves the more important commercial questions unanswered.

The questions that actually drive revenue are: who is on the verge of doing this? Who is doing it but using the wrong tool? Who is positioned to become an influential early adopter in a new technique or indication? What market dynamics — reimbursement shifts, competitive product launches, technology inflection points — will change the picture in 6 to 18 months?

Those questions require a different kind of intelligence infrastructure. Not a faster claims feed — a deeper analytical foundation. One that connects procedure-level data to market-level context, competitive dynamics, and strategic foresight.

“Volume data answers who is doing this. Strategic intelligence answers who is about to, why it matters, and what the competitive landscape looks like when they do.”

This is where the combination of SmartTRAK’s analyst-validated market intelligence and Alpha Sophia’s data-driven commercial analytics creates something that neither platform can replicate alone: a full-stack commercial intelligence capability that spans from market-level strategy to physician-level targeting.

The Winning Strategy: Layering Intelligence on Top of Targeting

The companies we see outperforming their markets aren’t abandoning physician targeting platforms. They’re using them as one layer in a richer commercial intelligence stack. Here’s what that looks like in practice:

• Market-level intelligence drives targeting strategy, not the other way around.
  Understanding where a technology category is in its adoption curve, which indications are gaining reimbursement traction, and which competitive products are winning or losing share provides the strategic frame that makes physician-level targeting meaningful.
• Competitive context makes the rep conversation different.
  When a rep knows not just that a physician does high volume, but that a competitor’s market share is declining in that therapeutic area, that a new reimbursement code is creating an opportunity, or that a key opinion leader in that geography is shifting their practice pattern — that’s a fundamentally different quality of conversation.
• Analyst-validated intelligence is defensible.
  The combination of SmartTRAK’s specialty-specific expert analyst layer — covering Orthopedics, Wound Care, Regenerative Medicine, and Neuro Therapy — with rigorous data analytics creates insight that can’t be generated by a model running on public claims data alone. It’s the difference between a dashboard and a diagnosis.
• Strategic and commercial intelligence compound over time.
  Procedure volume data tells you about the past. Market intelligence — when applied consistently and integrated into commercial strategy — builds a predictive advantage. Companies that invest in this layer now will have a structural edge that takes competitors years to replicate.

Continuing the Conversation at In2Data

These are the questions we’ll be putting in front of a room full of MedTech commercial leaders at SmartTRAK’s In2Data conference on November 4th at the Gaylord Hotel in Dallas.

Paul-Lukas Hoffschmidt will lead a dedicated session — “Beyond Sales Targeting: Unlocking Your Data’s Full Potential” — bringing real customer perspectives on what’s working, what’s failing, and what a more complete commercial intelligence strategy looks like across different market segments and company sizes.

The panel will draw on direct experience from companies that have moved beyond the target list and built intelligence-driven commercial operations — with measurable impact on pipeline quality, rep productivity, and market share growth.

Topics the session will explore include:

• Where physician targeting platforms deliver real ROI — and where they fall short
• How to layer market intelligence on top of claims-based targeting to elevate rep conversations
• The role of competitive intelligence and market context in shortening sales cycles
• Building a commercial data stack that scales with your organization — from startup to enterprise
• How SmartTRAK and Alpha Sophia’s combined approach creates a competitive edge across Ortho, Wound Care, Regen Med, and Neuro

In2Data is built around the idea that commercially focused AI and data intelligence — not product-focused AI — is the next frontier for MedTech growth. The companies that figure this out first will disproportionately capture market share as the industry’s AI maturity curve steepens.

We hope to see you in Dallas on November 4th. If you’re a MedTech commercial leader grappling with how to get more from your data investments, this is the conversation you’ve been waiting for.

To learn more about In2Data, just click the button below.

SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.